CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM) (“Enumeral” or the “Company”), a biotechnology company focused on discovering and developing novel antibody-based immunotherapies to help the immune system fight cancer and other diseases, today announced that it will present research findings on the Company’s novel class of anti-PD-1 antibodies in a poster at the AACR Annual Meeting 2016 in New Orleans.
